News Escend Press Releases Featured Jun 20, 2024 Escend Announces Poster Presentation at the Annual Meeting of the European Hematology Association from an Investigator-Initiated Phase I/II study evaluating ES-3000 in Myelodysplastic Syndrome (MDS) Jun 20, 2024 Jun 20, 2024 Jul 15, 2022 Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML) Jul 15, 2022 Jul 15, 2022 Dec 28, 2016 Escend Pharmaceuticals, Inc., Receives Second Orphan Drug Designation from FDA for ES-3000 Dec 28, 2016 Dec 28, 2016 Jun 2, 2016 Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000, its Lead Compound, in the Treatment of Chronic Myeloid Leukemia (CML) Jun 2, 2016 Jun 2, 2016
